Comparison of clinical and laboratory characteristics at diagnosis for 1354 patients with PMF stratified based on race (Black AA vs non-AA)
| Variables . | Black AA patients with PMF n = 88 . | Non-AA patients with PMF n = 1266 . | P-value . |
|---|---|---|---|
| Age in y, median (range) | 61 (19-86) | 65 (19-92) | .02 |
| Male, n (%) | 42 (48) | 792 (63) | < .01 |
| Driver mutation, n (%) | n = 63 | n = 853 | |
| JAK2 | 43 (68) | 573 (67) | .74 |
| CALR | 12 (19) | 169 (20) | |
| MPL | 5 (8) | 47 (6) | |
| Triple negative | 3 (5) | 64 (8) | |
| Type 1/like CALR vs others | 9 (14) | 136 (16) | .84 |
| Mutations on NGS, n (%) | |||
| TP53 | 1 of 34 (3) | 13 of 159 (8) | .24 |
| TET2 | 7 of 34 (21) | 7 of 49 (14) | .45 |
| ASXL1 | 8 of 34 (24) | 181 of 488 (37) | .10 |
| IDH1 | 0 of 34 (0) | 7 of 357 (2) | .26 |
| IDH2 | 0 of 34 (0) | 12 of 359 (3) | .14 |
| RUNX1 | 3 of 34 (9) | 7 of 218 (3) | .17 |
| N/KRAS | 3 of 34 (9) | 6 of 159 (4) | .24 |
| SRSF2 | 5 of 34 (15) | 72 of 511 (14) | .92 |
| EZH2 | 1 of 34 (3) | 17 of 447 (4) | .79 |
| U2AF1 | 4 of 34 (12) | 78 of 495 (16) | .52 |
| Palpable splenomegaly, n (%) | 37 of 86 (43) | 343 of 1233 (28) | < .01 |
| Transfusion-dependent, n (%) | 55 (63) | 854 (68) | .33 |
| Constitutional symptoms, n (%) | 55 (63) | 899 (71) | .10 |
| Arterial thrombosis at or before diagnosis, n (%) | 2 (2) | 134 (11) | < .01 |
| Venous thrombosis at or before diagnosis, n (%) | 6 (7) | 91 (7) | .89 |
| Arterial thrombosis after diagnosis, n (%) | 3 (3) | 68 (5) | .39 |
| Venous thrombosis after diagnosis, n (%) | 9 (10) | 70 (6) | .10 |
| Hemoglobin, g/dL, median (range) | 10.1 (4.8-15.5) | 10.2 (3.8-17.5) | .10 |
| Leukocyte count × 109/L, median (range) | 8.4 (0.9-81) | 8.8 (0.8-236) | .36 |
| Platelet count × 109/L, median (range) | 256 (13-1193) | 230 (6-2400) | .54 |
| Circulating blasts %, median (range) | 0.6 (0-15) | 0 (0-18) | .28 |
| Lactate dehydrogenase (LDH), U/L, median (range) | n = 61 493 (136-2910) | n = 995 498 (83-2530) | .28 |
| Karyotype, n(%) | n = 70 | n = 977 | .21 |
| Favorable | 56 (80) | 716 (73) | |
| Unfavorable | 14 (20) | 261 (27) | |
| DIPSS risk, n(%) | n = 88 | n = 1256 | < .01 |
| Low | 13 (15) | 186 (15) | |
| Intermediate-1 | 47 (53) | 462 (37) | |
| Intermediate-2 | 26 (30) | 497 (40) | |
| High | 2 (2) | 111 (9) | |
| DIPSS plus risk, n(%) | n = 70 | n = 1235 | < .01 |
| Low | 10 (14) | 150 (12) | |
| Intermediate-1 | 18 (26) | 211 (17) | |
| Intermediate-2 | 32 (46) | 463 (37) | |
| High | 10 (14) | 411 (33) | |
| Follow-up in y, median (range) | 3.2 (0.1-18.6) | 3.2 (0.1-30.9) | .95 |
| Leukemic transformation n (%) | 12 (14) | 117 (9) | .20 |
| ASCT, n (%) | 9 (10) | 67 (5) | .08 |
| Variables . | Black AA patients with PMF n = 88 . | Non-AA patients with PMF n = 1266 . | P-value . |
|---|---|---|---|
| Age in y, median (range) | 61 (19-86) | 65 (19-92) | .02 |
| Male, n (%) | 42 (48) | 792 (63) | < .01 |
| Driver mutation, n (%) | n = 63 | n = 853 | |
| JAK2 | 43 (68) | 573 (67) | .74 |
| CALR | 12 (19) | 169 (20) | |
| MPL | 5 (8) | 47 (6) | |
| Triple negative | 3 (5) | 64 (8) | |
| Type 1/like CALR vs others | 9 (14) | 136 (16) | .84 |
| Mutations on NGS, n (%) | |||
| TP53 | 1 of 34 (3) | 13 of 159 (8) | .24 |
| TET2 | 7 of 34 (21) | 7 of 49 (14) | .45 |
| ASXL1 | 8 of 34 (24) | 181 of 488 (37) | .10 |
| IDH1 | 0 of 34 (0) | 7 of 357 (2) | .26 |
| IDH2 | 0 of 34 (0) | 12 of 359 (3) | .14 |
| RUNX1 | 3 of 34 (9) | 7 of 218 (3) | .17 |
| N/KRAS | 3 of 34 (9) | 6 of 159 (4) | .24 |
| SRSF2 | 5 of 34 (15) | 72 of 511 (14) | .92 |
| EZH2 | 1 of 34 (3) | 17 of 447 (4) | .79 |
| U2AF1 | 4 of 34 (12) | 78 of 495 (16) | .52 |
| Palpable splenomegaly, n (%) | 37 of 86 (43) | 343 of 1233 (28) | < .01 |
| Transfusion-dependent, n (%) | 55 (63) | 854 (68) | .33 |
| Constitutional symptoms, n (%) | 55 (63) | 899 (71) | .10 |
| Arterial thrombosis at or before diagnosis, n (%) | 2 (2) | 134 (11) | < .01 |
| Venous thrombosis at or before diagnosis, n (%) | 6 (7) | 91 (7) | .89 |
| Arterial thrombosis after diagnosis, n (%) | 3 (3) | 68 (5) | .39 |
| Venous thrombosis after diagnosis, n (%) | 9 (10) | 70 (6) | .10 |
| Hemoglobin, g/dL, median (range) | 10.1 (4.8-15.5) | 10.2 (3.8-17.5) | .10 |
| Leukocyte count × 109/L, median (range) | 8.4 (0.9-81) | 8.8 (0.8-236) | .36 |
| Platelet count × 109/L, median (range) | 256 (13-1193) | 230 (6-2400) | .54 |
| Circulating blasts %, median (range) | 0.6 (0-15) | 0 (0-18) | .28 |
| Lactate dehydrogenase (LDH), U/L, median (range) | n = 61 493 (136-2910) | n = 995 498 (83-2530) | .28 |
| Karyotype, n(%) | n = 70 | n = 977 | .21 |
| Favorable | 56 (80) | 716 (73) | |
| Unfavorable | 14 (20) | 261 (27) | |
| DIPSS risk, n(%) | n = 88 | n = 1256 | < .01 |
| Low | 13 (15) | 186 (15) | |
| Intermediate-1 | 47 (53) | 462 (37) | |
| Intermediate-2 | 26 (30) | 497 (40) | |
| High | 2 (2) | 111 (9) | |
| DIPSS plus risk, n(%) | n = 70 | n = 1235 | < .01 |
| Low | 10 (14) | 150 (12) | |
| Intermediate-1 | 18 (26) | 211 (17) | |
| Intermediate-2 | 32 (46) | 463 (37) | |
| High | 10 (14) | 411 (33) | |
| Follow-up in y, median (range) | 3.2 (0.1-18.6) | 3.2 (0.1-30.9) | .95 |
| Leukemic transformation n (%) | 12 (14) | 117 (9) | .20 |
| ASCT, n (%) | 9 (10) | 67 (5) | .08 |
95% of the cohort were of Caucasian race. Significant P values are in bold.
ASCT, allogeneic stem cell transplant; DIPSS, dynamic international prognostic scoring system; NGS, next generation sequencing.